rilzabrutinib
Selected indexed studies
- Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study. (Blood, 2025) [PMID:40090011]
- Rilzabrutinib for the Treatment of Immune Thrombocytopenia. (Eur J Haematol, 2025) [PMID:40222822]
- Evaluating rilzabrutinib in the treatment of immune thrombocytopenia. (Immunotherapy, 2025) [PMID:40788289]
_Worker-drafted node — pending editorial review._
Connections
rilzabrutinib is a side effect of
Sources
- Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study. (2025) pubmed
- Rilzabrutinib for the Treatment of Immune Thrombocytopenia. (2025) pubmed
- Evaluating rilzabrutinib in the treatment of immune thrombocytopenia. (2025) pubmed
- Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. (2022) pubmed
- Rilzabrutinib in Antihistamine-Refractory Chronic Spontaneous Urticaria: The RILECSU Phase 2 Randomized Clinical Trial. (2025) pubmed
- Rilzabrutinib: First Approval. (2026) pubmed
- Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study. (2023) pubmed
- Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia. (2024) pubmed
- Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study. (2024) pubmed
- Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease. (2021) pubmed